{
    "clinical_study": {
        "@rank": "33399", 
        "arm_group": {
            "arm_group_label": "modified BuFlu, HSCT, elder/intolerable", 
            "description": "The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the new RIC regimen, containing of low\n      dose of Bu (9.6mg/kg)and fludarabine without ATG, is suitable and effective in treating aged\n      and/or intolerable patients with hematologic malignant disease, who undergoes allogenic stem\n      cell transplantation."
        }, 
        "brief_title": "Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients", 
        "condition": [
            "Leukemia", 
            "Myelodysplastic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosed of hematologic malignant disease\n\n          -  will undergo HLA matced HSCT\n\n          -  age >=55years\n\n          -  <55year and intolerable to standard myeloablative conditioning\n\n        Exclusion Criteria:\n\n          -  KPS status <70\n\n          -  cardiac EF<50%\n\n          -  creatine clearance <50 ml/min\n\n          -  ALT more than 10 times of upper normal limit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "55 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The study population is patients with hematologic malignant diseases, who will undergo HLA\n        matched HSCT."
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828619", 
            "org_study_id": "PKUIH-201303"
        }, 
        "intervention": {
            "arm_group_label": "modified BuFlu, HSCT, elder/intolerable", 
            "description": "The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. \u00d73days( on d -8 to -6); Flu30mg/m^2 i.v.\u00d75days(on d-6 to-2) and semustine 250 mg/m2 on d -3.", 
            "intervention_name": "modified BuFlu conditioning", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hematopoietic Stem Cell Transplantation", 
            "Busulfan", 
            "Fludarabine"
        ], 
        "lastchanged_date": "April 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100044"
                }, 
                "name": "Peking University People's Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases", 
        "overall_official": {
            "affiliation": "Peking University People's Hospital, Department of Hematology", 
            "last_name": "XiaoJun Huang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Ministry of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "stem cell engraftment", 
            "safety_issue": "No", 
            "time_frame": "30day post transplantation"
        }, 
        "reference": [
            {
                "PMID": "16871277", 
                "citation": "Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia. 2006 Oct;20(10):1661-72. Epub 2006 Jul 27. Review."
            }, 
            {
                "PMID": "15073038", 
                "citation": "de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 Aug 1;104(3):857-64. Epub 2004 Apr 8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828619"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University People's Hospital", 
            "investigator_full_name": "FENGRONG WANG", 
            "investigator_title": "Department of Hematology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "toxicity and treatment related mortality", 
            "safety_issue": "No", 
            "time_frame": "100day and 1 year post transplantation"
        }, 
        "source": "Peking University People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}